Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST-CKD: Branched-chain Amino Acids for Sarcopenia in Advanced CKD
NCT07437053Phase 1Not yet recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jul 2027
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Sarcopenia comparing Treatment group Valine with Treatment group EEA (2 arms). Primary endpoints: Skeletal muscle strength at 14 weeks, Muscle mass at 14 weeks and 2 more. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
valineessential amino acids-University of Oregon
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT07437053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437053.